Kymanox Executive Advisors
Whether you are a C-Suite executive requiring support on overall business strategy and program development or a member of a board looking for additional leadership support, Kymanox Executive Advisors are seasoned executives who have deep expertise in the life sciences industry, bringing products from inception through commercialization.
Kymanox Executive Advisors (KEA)

Mathias Romacker
Kymanox Executive Advisor

Paul Jansen
Kymanox Executive Advisor

Fran DeGrazio
Kymanox Executive Advisor

Evan Edwards
Chief Innovation Officer

Stephen M. Perry
Founder & CEO
Executive Leadership
Our seasoned executives have not only built and led companies and are recognized as leaders in their field, but have also successfully developed products from inception through commercialization.
Executive-level leaders are true experts in their fields driving strategies around combination products, product development, primary packaging, parenterals, drug delivery, connected devices, contract manufacturing, product strategy, business intelligence, competitive landscape, technical assessments, business case evaluations, CMO selection and assessments, and regulatory success assessments.

Helpful Links
Markets That Benefit from Kymanox Executive Advisors
Combination Products
Our experts understand the interaction between devices and drug products. Our experience includes injectables, nasal, respiratory, and more.
Biologics & Cell and Gene Therapy Services
We understand why “the product is the process” and how to implement solutions to your unique challenges.




Frequently Asked KEA Questions (FAQs)
How do I engage with the KEA team?
Please contact Michael Denzer, our VP of Technical Solutions at michael.denzer@kymanox.com. Engagements are flexible and right-fit to your needs.
How much does engagement with Kymanox Executive Advisors cost?
Each engagement is customized based on your need, the duration of work, and the KEA(s) being utilized. We will provide a customized Statement of Work (SOW) after an initial call to determine how we can help.
Read the Latest at Kymanox
Kymanox Acquires EU Based Anteris Medical and Anteris Helvetia
Leveraging the well-respected anteris brand and team, this acquisition extends Kymanox’s capabilities and geographic reach with a strong European presence
Friday, 03 February 2023
Morrisville, North Carolina, USA and Holzkirchen, Germany an...
Interview: Kymanox Executive Advisors Mathias Romacker, Fran DeGrazio & Paul Jansen
Kymanox Executive Advisors (KEAs) Mathias Romacker, Fran DeGrazio, and Paul Jansen sit down with Guy Furness to discuss what has driven Kymanox's rapid rise in the drug delivery space and what makes the consulting company's model so successful, as well...
Growing Happy Cells: Bioreactor Optimization
Biologics, including cell and gene therapies, have become a hot topic in the pharmaceutical industry as their therapeutic applications expand. Challenges of developing biologic drug products include scale-up for commercial manufacturing and production ...